Testosterone Cypionate Global Regulatory Status

FDA Approval History and NDA Record

Testosterone cypionate has been on the U.S. Market for longer than most practitioners realize. The FDA granted approval under NDA 011922 in 1979, making it one of the older androgen-replacement products still in active clinical use. The original sponsor was Upjohn (now Pfizer), though today the product is manufactured by multiple generic firms including Pfizer (Depo-Testosterone), Perrigo, and West-Ward Pharmaceuticals.

What the Original Approval Covered

The 1979 approval was narrow. It authorized testosterone cypionate intramuscular injection (100 mg/mL and 200 mg/mL concentrations) exclusively for males with primary hypogonadism (testicular failure) and hypogonadotropic hypogonadism (pituitary or hypothalamic origin). No pediatric indication, no female indication, and no off-label wellness use were sanctioned at that time.

Prescribing outside those two indications remains off-label, which has regulatory and liability implications for prescribers operating telehealth testosterone clinics. The FDA's current label, accessible via Drugs@FDA, lists the approved dose range as 50 to 400 mg administered intramuscularly every two to four weeks.

Generic Entry and Market Proliferation

Generic versions began entering the market in the 1980s. By 2025, the FDA's Orange Book lists more than a dozen approved testosterone cypionate products rated therapeutically equivalent (A-rated) to the reference listed drug. This proliferation matters from a regulatory standpoint: each generic ANDA references NDA 011922's safety data, meaning post-market safety changes to the reference label cascade to all generics through FDA's labeling synchronization requirements.

Pediatric and Female Use

The FDA has not approved testosterone cypionate for female hypogonadism or female sexual dysfunction. Use in women, when it occurs clinically, is off-label. The current label carries explicit language warning against use in women who are or may become pregnant, citing Category X teratogenicity data in animals. Pediatric use is similarly restricted, with the label warning that androgens can accelerate bone maturation and cause premature epiphyseal closure.

DEA Scheduling and Controlled Substance Status

Testosterone cypionate is a Schedule III controlled substance under the Controlled Substances Act (CSA), as codified by the Anabolic Steroid Control Act of 1990 and expanded in 2004. Schedule III status sits one tier below the most restrictive Schedule I and II categories but carries meaningful legal obligations.

What Schedule III Means in Practice

Prescribers must hold an active DEA registration to prescribe testosterone cypionate. Prescriptions are limited to a 90-day supply per fill at most state pharmacy boards, and refills are capped at five within a six-month window. Electronic prescribing for controlled substances (EPCS) is required in several states including New York, Minnesota, and Maine.

Telehealth prescribers face additional federal friction. The Ryan Haight Online Pharmacy Consumer Protection Act of 2008 historically required at least one in-person evaluation before a controlled substance could be prescribed via telemedicine. COVID-era DEA waivers temporarily suspended that requirement; as of 2025, DEA's proposed "telemedicine prescribing of controlled substances" rule continues to evolve, and practitioners should consult the DEA Diversion Control Division for current guidance.

Illicit Use and Enforcement

Schedule III scheduling does not merely restrict prescribers. It also makes unauthorized manufacture, distribution, and possession criminal offenses. The DEA's annual National Forensic Laboratory Information System data consistently identify testosterone (including the cypionate ester) among the most frequently seized anabolic steroids in the United States. Post-market surveillance through the FDA Adverse Event Reporting System (FAERS) captures misuse-related adverse events, which feed back into regulatory risk-benefit reassessments.

Current FDA Label: Indications, Dosing, and Contraindications

Approved Indications

The FDA label is explicit: testosterone cypionate is indicated for replacement therapy in males with primary or hypogonadotropic hypogonadism. The label gives two examples of acceptable clinical presentations: castration and Klinefelter syndrome for primary hypogonadism, and pituitary-hypothalamic injury from tumors or radiation for hypogonadotropic hypogonadism.

Age-related low testosterone (sometimes called "late-onset hypogonadism" or "andropause") is not an FDA-approved indication. The FDA issued a Drug Safety Communication in 2015 specifically cautioning against testosterone products for low testosterone due to aging alone, citing inadequate evidence of benefit and possible cardiovascular risk.

Dosing Parameters

The label specifies 50 to 400 mg injected intramuscularly every two to four weeks. In clinical practice, many physicians use smaller doses (100 to 200 mg) on a weekly or biweekly schedule to reduce peak-to-trough serum fluctuations, a dosing pattern supported by pharmacokinetic reasoning but not formally included in the approved label.

Contraindications

The label lists four absolute contraindications:

1. Known or suspected carcinoma of the prostate or breast in men.
2. Pregnancy (Category X).
3. Serious hepatic disease.
4. Known hypersensitivity to any component of the formulation, including the cottonseed oil vehicle.

Black Box Warning

The label carries a black box warning for virilization in women, particularly applicable when testosterone preparations are misused or administered to female sexual partners secondhand through skin contact with topical formulations. The warning specifically addresses transfer risk, though testosterone cypionate is injectable and the transfer pathway differs from gels or creams.

Post-Market Safety Additions: What Changed After 1979

The 1979 label was lean by modern standards. Decades of post-market surveillance, pharmacovigilance, and large clinical trials have added substantial safety language.

Cardiovascular Risk Warning (2015)

The FDA's 2015 Drug Safety Communication mandated a label change requiring all testosterone products to describe a possible increased risk of cardiovascular events, including heart attack and stroke. This action followed a review of published studies including a 2010 placebo-controlled trial in older men (Basaria et al., NEJM) that was stopped early due to excess cardiovascular events in the testosterone arm, and a 2014 retrospective cohort study in veterans showing increased cardiovascular event rates.

The T-Trials, a coordinated set of seven double-blind, placebo-controlled trials in 788 men aged 65 years or older with low testosterone, published in the New England Journal of Medicine in 2016, showed testosterone treatment increased coronary artery plaque volume by 0.52 percentage points (95% CI 0.12 to 0.91; P<0.001 for noncalcified plaque) compared to placebo [1]. The FDA cited these findings when reinforcing the cardiovascular language in the label.

Venous Thromboembolism Warning

In 2014, the FDA added a warning for deep vein thrombosis (DVT) and pulmonary embolism (PE) to all testosterone product labels. The agency acted after reviewing FAERS reports and published case series. The biological plausibility rests partly on testosterone's stimulation of erythropoiesis: elevated hematocrit increases blood viscosity and may predispose to thrombus formation.

Polycythemia

The label advises monitoring hematocrit before initiating therapy, at three to six months, and then annually. If hematocrit exceeds 54%, therapy should be stopped until it returns to a safe range, then restarted at a lower dose. The Endocrine Society's 2018 clinical practice guideline on testosterone therapy recommends checking hematocrit at the same intervals [as cited below in the guidelines section].

Sleep Apnea

Post-market case reports led to the addition of a warning noting that testosterone may worsen pre-existing obstructive sleep apnea. Patients should be screened for sleep apnea risk factors before starting therapy, particularly those with obesity (BMI <30 is generally considered lower risk, but higher BMI substantially increases concern).

Endocrine Society and AACE Clinical Guidelines

Clinical guidelines translate the FDA label into practical prescribing algorithms.

Endocrine Society 2018 Guideline

The Endocrine Society's 2018 guideline on testosterone therapy in men with hypogonadism states: "We suggest that clinicians measure testosterone levels in the morning on at least two occasions, using a reliable assay, before diagnosing androgen deficiency." The guideline recommends confirming a total testosterone below 300 ng/dL (10.4 nmol/L) with symptoms before initiating therapy.

The guideline also provides explicit monitoring checkpoints: serum testosterone at three to six months (target mid-normal range, approximately 400 to 700 ng/dL), hematocrit at three to six months and then annually, and a digital rectal exam plus PSA at three and twelve months for men over 40. These benchmarks are consistent with, though more detailed than, the FDA label's monitoring language.

AACE/ACE Position Statement

The American Association of Clinical Endocrinology's position on testosterone therapy aligns with the Endocrine Society on biochemical diagnosis thresholds and adds that testosterone should not be initiated if the patient has a hematocrit above 50%, untreated severe sleep apnea, or uncontrolled heart failure. AACE's guidance is available at aace.com.

International Regulatory Status

European Union

The European Medicines Agency has not issued a centralized European Public Assessment Report (EPAR) for testosterone cypionate specifically. Testosterone esters (including cypionate) are regulated at the member-state level. Germany (BfArM) and the United Kingdom (MHRA, post-Brexit) authorize testosterone products under national marketing authorizations.

In the EU, testosterone is a prescription-only medicine across all member states. The product most commonly dispensed in European clinical practice is testosterone undecanoate (Nebido, 1000 mg every 10 to 14 weeks) or testosterone enanthate, not cypionate. Testosterone cypionate is less common in European formularies, though it can be imported under named-patient or hospital exemption provisions in several countries.

United Kingdom

The MHRA classifies testosterone as a Schedule 4 Part 2 controlled drug under the Misuse of Drugs Regulations 2001. Prescription requirements mirror those in the U.S. With respect to legitimate medical use. Non-medical supply is a criminal offense under the Misuse of Drugs Act 1971.

Canada

Health Canada classifies testosterone cypionate as a Schedule IV controlled substance under the Controlled Drugs and Substances Act. It is approved under Drug Identification Number (DIN) for male hypogonadism. As in the U.S., prescribing for age-related low testosterone without confirmed biochemical hypogonadism is not supported by Health Canada's approved product monograph.

Australia

The Therapeutic Goods Administration (TGA) lists testosterone as a Schedule 4 (prescription only) substance under the Poisons Standard. Testosterone cypionate is available in Australia but requires a Special Access Scheme (SAS) or Authorised Prescriber pathway for certain clinical uses. The TGA has signaled increased scrutiny of online clinics prescribing testosterone without in-person assessment.

Countries Where Testosterone Is Heavily Restricted or Banned for Non-Medical Use

Several jurisdictions treat any non-medical possession as a serious criminal offense, including China, Japan, and most nations in the Gulf Cooperation Council (GCC). Athletes subject to World Anti-Doping Agency (WADA) rules face a four-year ban for testosterone use without a Therapeutic Use Exemption (TUE), regardless of local prescription status.

FDA Sentinel and Post-Market Surveillance Infrastructure

The FDA operates the Sentinel System, a distributed electronic database linking claims data from more than 100 million insured Americans. Testosterone products, including testosterone cypionate, are subjects of active Sentinel queries examining cardiovascular events, VTE, and prostate outcomes in real-world prescription populations.

A 2018 Sentinel analysis of testosterone therapy found that within 90 days of initiation, testosterone users had a higher rate of VTE events compared to age-matched controls not on androgen therapy, consistent with the label warning added in 2014. Prescribers can access FDA's Drug Safety Communications on testosterone at fda.gov/drugs.

FAERS data for testosterone (all esters combined) show cardiovascular events as the most frequently reported serious adverse event category, followed by polycythemia, injection site reactions, and mood disturbances. Because FAERS is a spontaneous reporting system, it cannot establish incidence rates or causality, but it does trigger label review cycles.

Off-Label Prescribing: What Is and Is Not Sanctioned

What Off-Label Means Legally

Off-label prescribing of testosterone cypionate is legal in the United States. Physicians may prescribe any FDA-approved drug for any indication once it clears approval for at least one indication. However, prescribing off-label does not transfer FDA's safety endorsement to the new use, and it shifts greater liability to the prescribing clinician.

Common Off-Label Uses in TRT Clinics

Telehealth and men's health clinics frequently prescribe testosterone cypionate for:

• Age-related low testosterone without confirmed biochemical hypogonadism.
• Female hypogonadism and female sexual interest/arousal disorder (FSIAD).
• Gender-affirming hormone therapy for transgender men (where testosterone enanthate or cypionate is a first-line agent per WPATH Standards of Care, Version 8).

None of these uses carry FDA approval for testosterone cypionate specifically, though some (particularly gender-affirming care) have strong guideline support from major medical organizations.

The FDA's 2015 Warning and Its Ongoing Weight

The 2015 FDA Drug Safety Communication remains the most cited regulatory document in disputes over testosterone prescribing. It stated: "The benefit and safety of these medications have not been established for the treatment of low testosterone levels due to aging, even if a man's symptoms seem related to low testosterone." Prescribers who document their rationale carefully, obtain informed consent, and follow Endocrine Society monitoring protocols are in a stronger defensible position than those who do not.

Compounded Testosterone Cypionate: A Separate Regulatory Lane

Compounded testosterone cypionate falls outside the FDA's NDA approval framework. 503A compounding pharmacies (patient-specific) and 503B outsourcing facilities (larger-volume, hospital supply) operate under different FDA oversight tiers defined by the Drug Quality and Security Act of 2013.

The FDA considers commercially available testosterone cypionate a product with an "essentially a copy" restriction: 503A pharmacies may compound it only if a licensed prescriber documents a clinical difference that justifies compounding over the commercial product (for example, a patient with a documented cottonseed oil allergy requiring a different carrier).

503B outsourcing facilities cannot compound essentially a copy of an FDA-approved drug without the drug being on FDA's shortage list. Testosterone cypionate has not appeared on the FDA Drug Shortage database as of early 2025, which limits 503B compounding of the standard formulation.

Monitoring Requirements Under the Label

The FDA label and clinical guidelines converge on a core monitoring protocol. Prescribers should check:

• Baseline: Serum total testosterone (morning, two samples), hematocrit, PSA (men over 40), lipid panel, and hepatic function.
• 3 to 6 months: Repeat testosterone (target mid-normal: 400 to 700 ng/dL), hematocrit, PSA. Adjust dose based on trough or mid-cycle levels depending on injection frequency.
• Annually: Full repeat of the above panel plus clinical assessment of symptom response.

The Endocrine Society guideline notes that if PSA rises more than 1.4 ng/mL above baseline within any 12-month period, or if PSA exceeds 4 ng/mL absolutely, urological referral is warranted before continuing therapy [2].

Key Statistics That Inform the Regulatory Conversation

Three data points appear most frequently in regulatory and clinical guidance documents:

1. In the T-Trials (N=788 men, mean age 72 years), testosterone treatment increased the coronary artery noncalcified plaque volume score by 0.52 percentage points compared to placebo (P<0.001), prompting ongoing FDA scrutiny of cardiovascular labeling [1].

2. A 2013 observational study in JAMA Internal Medicine (Finkle et al., N=55,593 prescriptions) found that the rate of non-fatal myocardial infarction was 36% higher in the 90 days after testosterone initiation compared with the 12 months before initiation, a finding the FDA cited when adding cardiovascular risk language to the label [3].

3. The Endocrine Society estimates that 2% to 6% of men on testosterone therapy will develop polycythemia (hematocrit above 54%), with the risk higher at doses above 200 mg every two weeks and in men who smoke or live at high altitude [2].